Mammalian cell-expressed therapeutic proteins are particularly vulnerable to contamination by
endogenous retrovirus-like particles (RVLPs). The Viresolve NFR filterwas designed to meet the critical requirement of manufacturing a safe and virus-freetherapeutic by retaining RVLPs by a minimum of six log reduction value (LRV). TheNFR designation refers to
retrovirus removal in a normal flow format. To qualify theproduct, we tested two model viruses: the 78 nm diameter
6 bacteriophage and the80-110 nm diameter Xenotropic Murine Leukemia Virus (X-MuLV). Robust retentionwas demonstrated over a wide range of process parameters. Viresolve NFR filters alsoretain other model adventitious viruses including 70-85 nm diameter Reovirus 3(Reo3), 70-90 nm diameter Adenovirus 2 (Ad2), and 53 nm diameter PR772 by >6LRV. In addition to these model viruses, the filter retains >7 LRV of both themycoplasma
Acholeplasma laidlawii and the bacterium
Brevundimonas diminuta.Protein passage is shown to be consistently high (95-100%) for a variety of therapeuticprotein products, including monoclonal antibodies. Characterization of the filter inspecific applications is made simple by availability of ultralow surface area (5 cm
2)disks, which are shown to scale linearly to the manufacturing scale pleated-filters.Viresolve NFR filters provide consistent water permeability performance (34-37 LMH/psi) and show very little plugging for all feedstocks evaluated. The Viresolve NFRfilter incorporates Retropore, a unique asymmetric polyethersulfone membrane, thesurface of which has been modified to minimize protein binding.